Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

The National Institute of Allergy and Infectious Diseases (NIAID), a subsidiary of National Institutes of Health is a research institute that provides technological and therapeutic solutions. The institute develops therapies, diagnostic tests, vaccines, and other technologies to understand, immunologic, treat and prevent infectious, and allergic diseases. It offers services such as grants and funding, research and training, and health information. NIAID supports basic and clinical research to understand the causes and mechanisms that lead to the development of allergic and immunologic diseases. The institute's research areas include infectious diseases such as tuberculosis and influenza, HIV/AIDS, biodefense; and immune-mediated diseases including asthma and allergy. NIAID is headquartered in Bethesda, Maryland, the US.

The National Institute of Allergy and Infectious Diseases-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 15

Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 16

Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 17

Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 18

Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 19

DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 20

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 21

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 22

RedHill Biopharma Enters into Agreement with NIAID 23

GlaxoSmithKline Enters into Research Agreement with NIAID 24

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 25

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

GenVec Enters into Research Agreement with LMIV 28

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 29

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 30

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 31

PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 33

Knopp Biosciences Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 34

Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 35

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 36

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 37

Licensing Agreements 38

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 38

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 39

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 40

The National Institute of Allergy and Infectious Diseases-Key Competitors 41

The National Institute of Allergy and Infectious Diseases-Key Employees 42

The National Institute of Allergy and Infectious Diseases-Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Recent Developments 44

Government and Public Interest 44

Sep 12, 2018: TechnoVax awarded USD 1.5 million NIH grant to further develop a universal VLP-based influenza vaccine 44

Aug 28, 2018: UTEP Scientists Awarded USD 6M to Improve Treatment for Chagas Disease 45

Aug 02, 2018: UMD-Led team receives USD 7.7 Million NIH grant for first-of-its-kind tick-borne disease research 46

Jul 25, 2018: HIV remission free of antiretroviral therapy is a feasible goal 47

Jul 11, 2018: NIAID scientists create 3D structure of 1918 influenza virus-like particles 48

Jun 29, 2018: Same Vaccine Concept for Ebola Appears Effective Against Nipah Virus 49

Jun 21, 2018: VTCRI scientist awarded USD 2 million grant from the National Institutes of Health to study the body's immune memory response 50

May 30, 2018: NIH scientists show how tularemia bacteria trick cells to cause disease 52

May 16, 2018: Lab-confirmed prenatal exposure to Zika is linked to cardiac defects in infants 53

Apr 25, 2018: Anti-HIV drug combination does not increase preterm birth risk, study suggests 54

Apr 16, 2018: Epstein-Barr virus protein can switch on risk genes for autoimmune diseases 55

Mar 27, 2018: NIAID Scientists Discover Rare Genetic Cause of Crohn's Disease 56

Mar 22, 2018: NIH scientists say advanced vaccines could limit future outbreaks 57

Mar 21, 2018: Islet transplantation improves quality of life for people with hard-to-control type 1 diabetes 58

Mar 19, 2018: Newly described human antibody prevents malaria in mice 60

Mar 09, 2018: NIH experts call for transformative research approach to end tuberculosis 61

Mar 08, 2018: NIAID scientists assess transmission risk of familial human prion diseases to mice 62

Mar 08, 2018: Monoclonal antibodies crucial to fighting emerging infectious diseases, say NIH officials 63

Mar 05, 2018: Broadly neutralizing antibody treatment may target viral reservoir in monkeys 64

Feb 28, 2018: NIAID unveils strategic plan for developing a universal influenza vaccine 65

Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 66

Feb 05, 2018: New Research Suggests Your Immune System Can Protect Against MRSA Infections 67

Jan 24, 2018: NIH begins large HIV treatment study in pregnant women 69

Jan 03, 2018: Stem cell transplant for severe scleroderma improves survival, quality of life 71

Dec 05, 2017: Scientists Find Potential Weapons for the Battle Against Antibiotic Resistance 73

Dec 04, 2017: Fighting HIV through a better delivery method of anti-retrovirals 75

Nov 30, 2017: New treatment investigated for brain tapeworm infection 76

Oct 24, 2017: Identifying the mechanism for a new class of antiviral drugs could hasten their approval 77

Oct 17, 2017: Pair of Discoveries Illuminate New Paths to Flu and Anthrax Treatments 78

Sep 28, 2017: Neuro-Immune Crosstalk in Allergic Asthma 80

Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 82

Sep 20, 2017: Texas Biomed Scientists part of USD 11.5 million NIH project aimed at combating drug resistance in the malaria parasite 84

Sep 05, 2017: Zika virus selectively infects and kills glioblastoma cells in mice 85

Aug 22, 2017: CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis 86

Aug 21, 2017: Texas Biomed part of team receiving five-year, USD 4.4 million NIH grant for novel TB vaccine testing 87

Jul 31, 2017: Biomedical Researcher Gets USD 1.9 Million to Study Influenza Vaccines and Cross-Protective Immunity Biomedical Researcher Gets USD 1.9 Million to Study Influenza Vaccines and Cross-Protective Immunity 89

Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 90

Jul 13, 2017: Experimental Zika Virus Vaccines Restrict In Utero Virus Transmission in Mice 91

Jun 19, 2017: USD 3.6 Million NIH Grant Awarded to NYBC Scientist for Research on River Blindness Vaccine 92

May 01, 2017: NIH Research Improves Health for People with Asthma 93

Apr 21, 2017: Researchers receive USD 9 million grant for research on drug-resistant malaria 95

Feb 01, 2017: Stem cell transplants may induce long-term remission of multiple sclerosis 96

Jan 17, 2017: NIAID Awards Paragon Bioservices a Multiple Award IDIQ Contract valued up to USD 159M for Preclinical Drug Development Services 97

Product News 98

Oct 03, 2017: Oak Therapeutics Announces Results of Bioequivalence Study of Company's Oral Dissolvable Strip for Tuberculosis 98

Jun 12, 2018: GenScript Supports the Development of a Novel HIV Vaccine 99

May 07, 2018: NIH clinical trial to track outcomes of kidney transplantation from HIV-positive donors to HIV-positive recipients 100

May 03, 2018: Bacteria therapy for eczema shows promise in NIH study 102

Mar 13, 2018: NIH scientists describe potential antibody approach for treating multidrug-resistant Klebsiella pneumoniae 104

Other Significant Developments 105

Apr 09, 2018: NIH Scientists Develop Macaque Model to Study Crimean-Congo Hemorrhagic Fever 105

Feb 21, 2018: NIH program to accelerate therapies for arthritis, lupus releases first datasets 106

Jan 24, 2017: NIH Advances Understanding of Defenses Against Antibiotic-Resistant Klebsiella Bacteria 107

Appendix 108

Methodology 108

About GlobalData 108

Contact Us 108

Disclaimer 108

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Key Facts 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

The National Institute of Allergy and Infectious Diseases, Deals By Therapy Area, 2012 to YTD 2018 10

The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 15

Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 16

Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 17

Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 18

Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 19

DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 20

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 21

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 22

RedHill Biopharma Enters into Agreement with NIAID 23

GlaxoSmithKline Enters into Research Agreement with NIAID 24

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 25

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

GenVec Enters into Research Agreement with LMIV 28

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 29

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 30

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 31

PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 33

Knopp Biosciences Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 34

Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 35

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 36

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 37

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 38

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 39

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 40

The National Institute of Allergy and Infectious Diseases, Key Competitors 41

The National Institute of Allergy and Infectious Diseases, Key Employees 42

The National Institute of Allergy and Infectious Diseases, Subsidiaries 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

The National Institute of Allergy and Infectious Diseases, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person